Evidence map›Paper›PMID 40104216›Full record

ArticleCell insight2025

Unveiling racial disparities in prostate cancer using an integrative genomic and transcriptomic analysis.

Abdalla Elbialy, Akshay Sood, Shang-Jui Wang, Peng Wang, Ahmed Fadiel, Anil V Parwani, Steven Huang, Gennady Shvets, Nagireddy Putluri, Jenny Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abdalla ElbialyOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Akshay SoodOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Shang-Jui WangOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Peng WangOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Ahmed FadielComputational Oncology Unit, The University of Chicago Comprehensive Cancer Center, 900 E 57th Street, KCBD Bldg., STE 4144, Chicago, IL, 60637, USA.
Anil V ParwaniOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Steven HuangSchool of Applied and Engineering Physics, Cornell University, Ithaca, NY, 14850, USA.
Gennady ShvetsSchool of Applied and Engineering Physics, Cornell University, Ithaca, NY, 14850, USA.
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
Jenny LiOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Xuefeng LiuOSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.

Funding

Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA menR01CA276474 · NCI · OHIO STATE UNIVERSITY · PI Xuefeng Liu · 2023 to 2026
$2.1M
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)R01CA222148 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2019 to 2022
$1.9M
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder CancerU01CA278927 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2023 to 2025
$1.8M
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer ClinicsR33CA258016 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2021 to 2023
$1.2M
NCI NIH HHS R01 CA222148NCI NIH HHS R01 CA276474NCI NIH HHS R33 CA258016NCI NIH HHS U01 CA278927
6 · The paper itself

Abstract

Prostate cancer exhibits significant racial disparities, with African American (AA) individuals showing ∼64% higher incidence and 2.3 times greater mortality rates compared to their Caucasian (CA) counterparts. Understanding the complex interplay of genetic, environmental, lifestyle, socioeconomic, and healthcare access factors is crucial for developing effective interventions to reduce this disproportionate burden. This study aims to uncover the genetic and transcriptomic differences driving these disparities through a comprehensive analysis using RNA sequencing (RNA-seq) and exome sequencing of prostate cancer tissues from both Black and White patients. Our transcriptomics analysis revealed enhanced activity in pathways linked to immune response and cellular interactions in AA prostate cancer samples, with notable regulation by histone-associated transcription factors (HIST1H1A, HIST1H1D, and HIST1H1B) suggests potential involvement of histone modification mechanisms. Additionally, pseudogenes and long non-coding RNAs (lncRNAs) among the regulated genes indicate non-coding elements' role in these disparities. Exome sequencing identified unique variants in AA patient samples within key genes, including TP73 (tumor suppression), XYLB (metabolism), ALDH4A1 (oxidative stress), PTPRB (cellular signaling), and HLA-DRB5 (immune response). These genetic variations likely contribute to disease progression and therapy response disparities. This study highlights the importance of considering genetic and epigenetic variations in developing tailored therapeutic approaches to improve treatment efficacy and reduce mortality rates across diverse populations.

Indexed as

Differential analysisEtiologyGenomicsProstate cancerRacial disparitiesTranscriptomics

Identifiers

PMID40104216
PMCPMC11914995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.